Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida®) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms

• Hauptverfasser: Claudiu T. Supuran (Verfasst von), Alessio Nocentini (Verfasst von), Elena Yakubova (Verfasst von), Nikolay Savchuk (Verfasst von), Stanislav Kalinin (Verfasst von), Mikhail Krasavin (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

The non-nucleoside reverse transcriptase inhibitor VM1500A is approved for the treatment of HIV/AIDS in its N-acyl sulphonamide prodrug form elsulfavirine (Elpida®). Biochemical profiling against twelve human carbonic anhydrase (CA, EC 4.2.1.1) isoforms showed that while elsulfavirine was a weak inh...